ライフサイエンスコーパス: estramustine

1 th a fluorescently labeled steroid analogue, estramustine.

2 (grade 1 to 2) nausea and fatigue related to estramustine.

3 ABC2 mRNA sensitized the resistant cells to estramustine.

4 e had no effect on direct labeling with [14C]estramustine.

5 lay a role in the response to the effects of estramustine.

6 1-hour infusions of 60 to 100 mg/m(2)), oral estramustine (10 mg/kg), and carboplatin (area under the

7 Estramustine 280 mg PO tid was administered 1 hour befor

8 Patients were treated with oral estramustine 280 mg tid and oral etoposide 100 mg/d for

9 es of docetaxel (70 mg/m2) every 21 days and estramustine 280 mg tid on days 1 through 5.

10 The cellular targets for estramustine, an antitumor drug used in the treatment of

11 6.3 months in the group given docetaxel and estramustine and 3.2 months in the group given mitoxantr

12 , 338 were assigned to receive docetaxel and estramustine and 336 to receive mitoxantrone and prednis

13 yzed data from sequential phase II trials of estramustine and etoposide.

14 etoconazole and doxorubicin alternating with estramustine and vinblastine.

15 nd doxorubicin alternating with vinblastine, estramustine, and androgen ablation followed by prostate

16 administration of docetaxel 70 mg/m(2), oral estramustine, and low-dose daily hydrocortisone in men w

17 blastine/estramustine (KA/VE) or paclitaxel, estramustine, and oral etoposide (TEE).

18 The combination of IV paclitaxel, oral estramustine, and oral etoposide is active in patients w

19 Bevacizumab, estramustine, and sunitinib should not be offered.

20 cess toxicity are observed with bevacizumab, estramustine, and sunitinib.

21 f colchicine to tubulin was not inhibited by estramustine as detected by fluorescence and DEAE filter

22 ival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and predniso

23 ties of Pt(IV) derivatives of cisplatin with estramustine at the first axial position, which is known

24 These results encourage further study of estramustine-based antimicrotubule drug combinations in

25 , a variety of nonhormonal agents, including estramustine-based therapy, suramin, mitoxantrone, and d

26 doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant ph

27 The estramustine binding site on tubulin is therefore distin

28 The affinity constant for estramustine binding to tubulin was determined by equili

29 , changing the second axial ligand in the Pt-estramustine complex has a significant effect on the mod

30 t prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and prednisone (MP).

31 Estramustine did not affect [3H]vinblastine binding, and

32 Pharmacokinetics of EMP and the metabolites estramustine (EaM), estromustine (EoM), estradiol, and e

33 Estramustine (EM), an antimicrotubule agent, is effectiv

34 s indicated its role in cholesterol/steroid (estramustine, estradiol, and progesterone) trafficking/s

35 doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen dep

36 d the covalent labeling of tubulin with [14C]estramustine in a dose-dependent fashion and were noncom

37 bulin, and this was inhibited with unlabeled estramustine in a dose-dependent manner.

38 The use of estramustine in combination with other cytotoxic agents

39 c carcinoma cells, the incorporation of [14C]estramustine into the beta III isotype of tubulin was fo

40 ded phase II dose of docetaxel combined with estramustine is 70 mg/m2 in MPT patients and 60 mg/m2 in

41 ole/doxorubicin alternating with vinblastine/estramustine (KA/VE) or paclitaxel, estramustine, and or

42 axol, the antimitotic mechanism of action of estramustine may be due to kinetic stabilization of spin

43 bined suppressive effects of vinblastine and estramustine on the rate and extent of shortening and dy

44 Estramustine only weakly inhibits polymerization of puri

45 ials have shown that docetaxel combined with estramustine or corticosteroids improves survival in met

46 y 2 weeks off, either alone or together with estramustine phosphate (EM-V) 600 mg/m(2) PO days 1 thro

47 We sought to determine the tolerance of estramustine phosphate (EMP) combined with a 3-hour pacl

48 Estramustine phosphate was given orally beginning on wee

49 Ixabepilone, with or without estramustine phosphate, is well tolerated and has antitu

50 on and overexpression of ABC2 contributes to estramustine resistance and provides the first indicatio

51 Since this isotype is overexpressed in estramustine resistant human prostate carcinoma cells, t

52 ene is amplified approximately 6-fold in the estramustine-resistant cells.

53 An estramustine-resistant human ovarian carcinoma cell line

54 ty labeling of microtubule protein with [14C]estramustine resulted in the labeling of both alpha- and

55 Estramustine strongly reduced the rate and extent both o

56 However, by video microscopy, we find that estramustine strongly stabilizes growing and shortening

57 ommon among patients receiving docetaxel and estramustine than among those receiving mitoxantrone and

58 was longer in the group given docetaxel and estramustine than in the group given mitoxantrone and pr

59 ents, each given in 21-day cycles: 280 mg of estramustine three times daily on days 1 through 5, 60 m

60 noncompetitive inhibitors of the binding of estramustine to tubulin.

61 [14C]Estramustine was incorporated into both the soluble and

62 served that the rate of efflux of dansylated estramustine was increased in SKEM compared with control

63 The interaction of the antimitotic agent estramustine with bovine microtubule proteins and purifi

64 We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men wi

65 for the benefit derived from combined use of estramustine with vinblastine or taxol, two other drugs